Mount Sinai Researchers Report Increasing Incidence of Early-Onset Colorectal Precancerous Lesions in First-of-Its-Kind Study of Patients Under Age 50

“Many clinicians are surprised when they find a precancerous polyp in someone younger than age 45. Our data provide new insights into how common these lesions are. Our data also suggest that clinically important lesions occur about five years earlier in individuals with a family history of colorectal cancer, compared to those without a family history,” says Dr. Itzkowitz. “That is why it is very important to take a good family history.”

The Doctor’s Oldest Tool

We overestimate the value of reasoning and facts. We believe in our clinical authority. We expect patients to behave rationally. But we all develop our beliefs through interactions with other people — what you believe depends on whom you trust.

“Cancer Family. The Search for the Cause of Hereditary Colorectal Cancer.” 

“The book explains his research ingrained with his very captivating family story. Boland discovered that the key factor in his family’s history of cancer was a hereditary mutation of a gene that caused, what he named, “Lynch Syndrome.””

You are the Real Product….

Let’s be clear: DNA companies offer you cheap DNA analysis not because they want to help you find your ancestors and living relatives, or your precise ethnicity, or your possible risk for developing various medical conditions, but for the same reasons Google offers you free searches, or Facebook a free social media universe. Once you opt in to sharing your data, you are the product.

Realising the potential of genomic technologies in cancer care: Implementing the ‘Cancer Diagnostic and Treatment for All’

The EU-wide approach should be applied beyond COVID-19. Cancer is a pandemic of its own, representing a real threat to European citizens and societies. Its already high prevalence is projected to continue to increase. 

Personalised medicine, through wide and timely access to biomarker testing, has the potential to transform cancer care and provide significant benefits to people living with cancer, healthcare systems and societies in general. It can fundamentally change what it means to receive a cancer diagnosis and live with cancer. Yet throughout the EU, uptake of genomic technologies for biomarker testing remains sub-optimal owing to a range of factors, including low awareness, inadequate infrastructure and lack of EU guidance on the value of testing.

A working group of leading experts and stakeholders from the EU oncology community was convened to create a report with actionable policy recommendations to address barriers to the delivery of personalised medicine – and specifically to support the implementation of one flagship in Europe’s Beating Cancer Plan, ‘Cancer Diagnostic and Treatment for All’ initiative. The recommendations call on the European Commission to:

  1. Lead awareness campaigns to increase understanding of the benefits of biomarker testing
  2. Develop EU-wide guidance on personalised medicine, including recommendations on biomarker testing as an indicator of quality in cancer care
  3. Build the infrastructure required for optimal uptake of biomarker testing
  4. Facilitate the development of specialised knowledge, including undergraduate, post-graduate and ongoing professional training in personalised medicine
  5. Mobilise resources to promote equal access to personalised medicine


Much of what upsets us is outside the control of those doing the upsetting. Remembering that can reduce a lot of the frustration we feel over late deliveries, call centres, over-stretched health services and more. We still won’t like these experiences but we can hope to keep our stress and frustration levels to a minimum.
Try: Thinking of annoying experiences you expect to have today, decide in advance to maintain a background awareness of your breathing – to keep presence of mind – while going through them.(Padraig O’Morain)

Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/ Association of Coloproctologists of Great Britain and Ireland (ACPGBI)/ United Kingdom Cancer Genetics Group (UKCGG)

These guidelines are primarily aimed at healthcare professionals and address:

  • Who should have surveillance?
  • When should surveillance take place?
  • What else can we do to prevent cancer?
  • What kind of surgery should we perform in people with hereditary cancer risk?
  • Who is eligible for gene testing, and what kind of testing should we perform?
%d bloggers like this: